Posaconazole
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Posaconazole: From [Indication Not on File] to Pneumocystosis
One-Sentence Summary
Posaconazole is a broad-spectrum triazole antifungal agent; this evidence pack does not contain its original approved indication or mechanism-of-action data. The TxGNN model predicts it may be effective for Pneumocystosis, currently supported by 2 clinical trials and 5 publications, though none directly test posaconazole against this indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in evidence pack (no license or original-indication data on file) |
| Predicted New Indication | Pneumocystosis |
| TxGNN Prediction Score | 99.77% |
| Evidence Level | L3 |
| New Zealand Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for posaconazole in this evidence pack. Based on general pharmacological knowledge, posaconazole is a broad-spectrum triazole antifungal that inhibits fungal 14-α-demethylase (Erg11/Cyp51), blocking ergosterol synthesis in the fungal cell membrane. It is established for prophylaxis and treatment of invasive fungal infections — notably Aspergillus and Candida species — in immunocompromised patients such as allogeneic haematopoietic stem cell transplant (HSCT) recipients and neutropenic patients.
Pneumocystosis (Pneumocystis jirovecii pneumonia) occurs in the same high-risk immunocompromised population — HSCT recipients, GVHD patients, and those on prolonged immunosuppression — that posaconazole's established antifungal-prophylaxis role already targets. This overlap in patient population is the main mechanistic rationale surfaced by the supporting literature.
However, the connection is largely indirect: the strongest clinical trial identified (NCT04368559) evaluates rezafungin against a "standard antimicrobial regimen" for invasive fungal disease prevention post-transplant, with posaconazole plausibly representing part of that standard-of-care comparator rather than being the tested intervention. Pneumocystis also has atypical fungal cell-wall/membrane biology (limited ergosterol dependence in some life stages), which is why azoles are not first-line PCP therapy in current clinical practice. This mechanistic caveat should be weighed against the TxGNN score.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT04368559 | Phase 3 | Completed | 602 | Compared IV rezafungin vs. standard antimicrobial regimen for prevention of invasive fungal disease in allogeneic HSCT recipients; posaconazole is a likely component of the standard-of-care comparator arm rather than the studied agent |
| NCT06859424 | Phase 2 | Recruiting | 358 | Platform trial comparing post-transplant cyclophosphamide-based GVHD prophylaxis regimens in mismatched unrelated donor PBSC transplant; not a direct posaconazole efficacy trial |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 35596686 | 2022 | Observational (retrospective) | Transplant Infectious Disease | Reviewed infectious complications, including fungal infection, in acute GVHD after liver transplantation at Mayo Clinic |
| 41232547 | 2025 | Guideline/Review | The Lancet Infectious Diseases | UK best-practice update on diagnosis of serious fungal diseases, including Pneumocystis, reflecting shift to non-culture-based testing |
| 41362140 | 2025 | Guideline/Review | Chinese Journal of Tuberculosis and Respiratory Diseases | 2025 clinical practice guideline for diagnosis/management of invasive pulmonary fungal disease |
| 26901377 | 2016 | Review | Swiss Medical Weekly | Overview of invasive candidiasis, aspergillosis, cryptococcosis, and Pneumocystis pneumonia; notes posaconazole's role in reducing invasive candidiasis via antifungal prophylaxis |
| 21973267 | 2011 | Review (pharmacokinetics) | Clinical Pharmacokinetics | Reviews pulmonary epithelial lining fluid penetration of antifungal and other anti-infective agents |
New Zealand Market Information
No New Zealand market authorizations are on file — posaconazole is not currently marketed in New Zealand under this evidence pack (0 licenses recorded).
Safety Considerations
Please refer to the package insert for safety information. No warnings, contraindications, or drug-interaction data were returned for posaconazole in this evidence pack (DDI query status: not found).
Conclusion and Next Steps
Decision: Hold
Rationale:
- The clinical trial and literature evidence linking posaconazole specifically to Pneumocystosis is indirect (posaconazole appears as a likely standard-of-care comparator, not the studied intervention), and mechanistic plausibility is uncertain given azoles' limited role in PCP treatment.
- A blocking data gap exists: no TFDA/package-insert safety data (warnings, contraindications, DDI) is available, so the candidate cannot pass initial safety screening (S1), and the drug is not currently marketed in New Zealand.
To proceed, the following is needed:
- TFDA package insert (warnings/contraindications) — blocking gap, obtain via TFDA official site
- Confirmed mechanism of action from DrugBank
- Direct evidence (trial or case series) of posaconazole efficacy specifically against Pneumocystis jirovecii, rather than as part of a broader prophylaxis regimen comparator
- Confirmation of original approved indication(s) and any existing regulatory filings, given none are currently on file
- New Zealand regulatory pathway assessment, since the drug is not currently marketed there
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.